← FDA DRUG APPROVALS

FDA ANDA · ANDA077321

LISINOPRIL

Sponsor: LUPIN

APPLICATION
ANDA077321
TYPE
ANDA
ORIGINAL APPROVAL
2005-09-09
LATEST ACTION
2020-04-27
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LISINOPRILPrescription
LISINOPRIL 5MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 30MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 10MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 2.5MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 40MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 20MG · TABLET · ORAL

Approval history

2020-04-27Labeling · Supplement 38 · standardAP
2020-04-27Labeling · Supplement 41 · standardAP
2016-02-18Labeling · Supplement 35 · standardAP
2015-04-09Labeling · Supplement 24AP
2015-04-09Labeling · Supplement 27 · standardAP
2015-04-09Labeling · Supplement 25 · standardAP
2015-04-09Labeling · Supplement 31 · standardAP
2011-02-04Labeling · Supplement 17AP
2009-11-18Labeling · Supplement 12AP
2009-05-29Labeling · Supplement 15AP
2007-01-30Labeling · Supplement 2AP
2006-08-08Labeling · Supplement 4AP
2005-09-09OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →